Lupin Ltd
NSE:LUPIN
US |
Fubotv Inc
NYSE:FUBO
|
Media
|
|
US |
Bank of America Corp
NYSE:BAC
|
Banking
|
|
US |
Palantir Technologies Inc
NYSE:PLTR
|
Technology
|
|
US |
C
|
C3.ai Inc
NYSE:AI
|
Technology
|
US |
Uber Technologies Inc
NYSE:UBER
|
Road & Rail
|
|
CN |
NIO Inc
NYSE:NIO
|
Automobiles
|
|
US |
Fluor Corp
NYSE:FLR
|
Construction
|
|
US |
Jacobs Engineering Group Inc
NYSE:J
|
Professional Services
|
|
US |
TopBuild Corp
NYSE:BLD
|
Consumer products
|
|
US |
Abbott Laboratories
NYSE:ABT
|
Health Care
|
|
US |
Chevron Corp
NYSE:CVX
|
Energy
|
|
US |
Occidental Petroleum Corp
NYSE:OXY
|
Energy
|
|
US |
Matrix Service Co
NASDAQ:MTRX
|
Construction
|
|
US |
Automatic Data Processing Inc
NASDAQ:ADP
|
Technology
|
|
US |
Qualcomm Inc
NASDAQ:QCOM
|
Semiconductors
|
|
US |
Ambarella Inc
NASDAQ:AMBA
|
Semiconductors
|
Utilize notes to systematically review your investment decisions. By reflecting on past outcomes, you can discern effective strategies and identify those that underperformed. This continuous feedback loop enables you to adapt and refine your approach, optimizing for future success.
Each note serves as a learning point, offering insights into your decision-making processes. Over time, you'll accumulate a personalized database of knowledge, enhancing your ability to make informed decisions quickly and effectively.
With a comprehensive record of your investment history at your fingertips, you can compare current opportunities against past experiences. This not only bolsters your confidence but also ensures that each decision is grounded in a well-documented rationale.
Do you really want to delete this note?
This action cannot be undone.
52 Week Range |
1 198.15
2 290.2
|
Price Target |
|
We'll email you a reminder when the closing price reaches INR.
Choose the stock you wish to monitor with a price alert.
Fubotv Inc
NYSE:FUBO
|
US | |
Bank of America Corp
NYSE:BAC
|
US | |
Palantir Technologies Inc
NYSE:PLTR
|
US | |
C
|
C3.ai Inc
NYSE:AI
|
US |
Uber Technologies Inc
NYSE:UBER
|
US | |
NIO Inc
NYSE:NIO
|
CN | |
Fluor Corp
NYSE:FLR
|
US | |
Jacobs Engineering Group Inc
NYSE:J
|
US | |
TopBuild Corp
NYSE:BLD
|
US | |
Abbott Laboratories
NYSE:ABT
|
US | |
Chevron Corp
NYSE:CVX
|
US | |
Occidental Petroleum Corp
NYSE:OXY
|
US | |
Matrix Service Co
NASDAQ:MTRX
|
US | |
Automatic Data Processing Inc
NASDAQ:ADP
|
US | |
Qualcomm Inc
NASDAQ:QCOM
|
US | |
Ambarella Inc
NASDAQ:AMBA
|
US |
This alert will be permanently deleted.
Intrinsic Value
The intrinsic value of one LUPIN stock under the Base Case scenario is 1 418.64 INR. Compared to the current market price of 2 071.35 INR, Lupin Ltd is Overvalued by 32%.
The Intrinsic Value is calculated as the average of DCF and Relative values:
Valuation Backtest
Lupin Ltd
Uncover deeper insights with the Valuation Backtest. Learn how current stock valuations stack up against historical averages to gauge true investment potential.
Start backtest now and learn if your stock is truly undervalued or overvalued!
Stock is trading at its lowest valuation over the past 5 years.
To access the results of this valuation backtest, please register an account with us. Registration is quick and gives you instant access to insights on 3 stocks per week for free.
The backtest for LUPIN cannot be conducted due to limitations such as insufficient data or other constraints. Please select a different stock or adjust your settings.
Fundamental Analysis
Economic Moat
Lupin Ltd
Select up to 3 indicators:
Select up to 3 indicators:
Months
Months
Months
Months
Select up to 2 periods:
Lupin Ltd. is a global pharmaceutical powerhouse rooted in Mumbai, India, renowned for its commitment to providing high-quality, affordable medicines across a spectrum of therapeutic areas. Founded in 1968, this rapidly growing company has carved a niche in generics, specialty pharmaceuticals, and biotechnology. With a robust portfolio that includes over 1,500 products across various disciplines, particularly in cardiovascular, CNS, and anti-infective medications, Lupin has established itself as a key player in the global healthcare ecosystem. The company's strategic focus on research and development ensures a steady pipeline of innovative solutions tailored to meet the needs of patients and...
Lupin Ltd. is a global pharmaceutical powerhouse rooted in Mumbai, India, renowned for its commitment to providing high-quality, affordable medicines across a spectrum of therapeutic areas. Founded in 1968, this rapidly growing company has carved a niche in generics, specialty pharmaceuticals, and biotechnology. With a robust portfolio that includes over 1,500 products across various disciplines, particularly in cardiovascular, CNS, and anti-infective medications, Lupin has established itself as a key player in the global healthcare ecosystem. The company's strategic focus on research and development ensures a steady pipeline of innovative solutions tailored to meet the needs of patients and healthcare providers alike, positioning Lupin as a dynamic leader in the pharmaceutical industry.
Driven by a global vision, Lupin operates in over 100 countries and has earned a reputation for excellence through its extensive manufacturing capabilities and adherence to stringent quality standards. The firm’s dedication to expanding its presence in developed markets, particularly in the U.S. and Europe, underscores its ambition to enhance healthcare access worldwide. For investors, Lupin represents an opportunity characterized by solid growth potential, as it continuously invests in R&D, strengthens its market position, and adapts to the evolving landscape of global healthcare. With a commitment to sustainability and a focus on creating value for stakeholders, Lupin Ltd. not only aims to thrive financially but also to enrich the lives of millions through its innovative healthcare solutions.
Lupin Ltd. is a major global player in the pharmaceutical industry, headquartered in Mumbai, India. The company operates through several core business segments, which include:
-
Generics: This segment involves the manufacturing and marketing of generic medicines. Lupin is known for its wide portfolio of generic drugs, including oral solid dosage forms, injectables, and respiratory products. The company markets these products in various international markets, particularly in the United States.
-
Branded Formulations: In addition to generics, Lupin develops and sells branded formulations, particularly in emerging markets. This segment includes both prescription medicines and over-the-counter products, addressing therapeutic areas like cardiovascular, diabetes, and CNS disorders.
-
API (Active Pharmaceutical Ingredients): Lupin manufactures APIs for its own formulations as well as for third-party customers. This segment allows the company to ensure quality control and cost-effectiveness in its drug manufacturing processes.
-
Biosimilars: Recognizing the growing potential in the biologics market, Lupin is also investing in the development of biosimilars. This includes products that have similar efficacy and safety profiles to existing biologic drugs, allowing for more affordable treatment options.
-
Over-the-Counter (OTC) Products: Lupin has a growing portfolio of OTC products, aimed at addressing everyday health needs. This segment targets a broad consumer base, providing healthcare solutions without the need for prescriptions.
-
Research and Development (R&D): While not a segment in the traditional sense, R&D is crucial for Lupin's growth strategy. The company invests significantly in research to develop innovative products, enhance existing formulations, and explore new therapeutic areas.
These core business segments allow Lupin to maintain a diverse portfolio, offering a range of pharmaceutical products that cater to varying global healthcare needs, while also strategically positioning the company for future growth in the competitive pharmaceutical landscape.
Lupin Ltd, as a prominent player in the pharmaceutical industry, possesses several unique competitive advantages that distinguish it from its rivals. Here are some key factors:
-
Diverse Product Portfolio: Lupin has a vast and well-diversified product portfolio that spans across various therapeutic categories, including anti-infectives, cardiology, diabetes, and CNS (central nervous system) disorders. This diversification allows the company to mitigate risks associated with dependence on a single market segment.
-
Strong Research & Development (R&D): Lupin invests significantly in R&D, which enables it to innovate and develop new drugs. A robust pipeline of generic and specialty pharmaceuticals enhances its competitive position, particularly in complex generics and biosimilars.
-
Global Presence: Lupin operates in over 100 countries, including key markets like the U.S., Europe, and Japan. This global reach allows for a diversified revenue base and reduces dependence on any single market.
-
Cost Efficiency: The company has established efficient manufacturing processes and a substantial production capacity. This cost structure advantage enables Lupin to compete effectively on price while maintaining quality.
-
Regulatory Expertise: Having successfully navigated various regulatory environments, including stringent U.S. FDA approvals, Lupin's knowledge and experience in compliance gives it an edge in bringing products to market successfully.
-
Strategic Collaborations and Partnerships: Building strategic alliances with other pharmaceuticals, biotech firms, and research institutions enables Lupin to access new technologies and expand its product offerings, further strengthening its competitive position.
-
Strong Brand Recognition: Lupin has built a strong brand reputation, particularly in the generic drugs sector. This trust can drive customer loyalty and lead to higher sales volumes in both developed and emerging markets.
-
Focus on Emerging Markets: With a keen eye on emerging markets, Lupin has positioned itself to benefit from increasing healthcare demands in these regions, which often experience significant growth relative to developed markets.
Together, these competitive advantages enable Lupin Ltd to navigate challenges in the pharmaceutical industry effectively, drive sustainable growth, and maintain a strong market position.
Lupin Ltd, a major player in the pharmaceutical industry, faces several risks and challenges that could impact its performance in the near future. Here are some key areas to consider:
-
Regulatory Challenges:
- Compliance Issues: The pharmaceutical industry is heavily regulated, and non-compliance can lead to fines, product recalls, or bans.
- Approval Delays: Delays in the approval of new drugs by regulatory bodies like the FDA can affect revenue projections.
-
Market Competition:
- Generic Drug Competition: As a significant manufacturer of generic drugs, Lupin faces intense competition from other generic pharmaceutical companies, impacting pricing and market share.
- Innovative Products: The pharmaceutical space is increasingly driven by innovation. Companies releasing ground-breaking drugs could overshadow Lupin's offerings.
-
Pricing Pressures:
- Reduced Pricing Power: Pricing pressures from healthcare providers, insurers, and government bodies can limit profit margins, especially in key markets like the U.S.
- Drug Price Reforms: Potential policy reforms aimed at lowering drug prices can affect revenues.
-
Supply Chain Disruptions:
- Raw Material Availability: Global supply chain issues, including those caused by geopolitical tensions or pandemics, can affect the availability and cost of raw materials.
- Manufacturing Challenges: Any disruptions in manufacturing due to labor shortages, facility issues, or quality control problems can impact product availability.
-
Research and Development Risks:
- High R&D Costs: Developing new drugs is expensive and time-consuming, with no guaranteed success.
- Pipeline Management: The success of new products in the pipeline is critical. Failures or delays can significantly hinder growth prospects.
-
Geopolitical Risks:
- Trade Policies: Changes in trade policies or tariffs can impact the cost structure of importing/exporting goods.
- Market Access: Political instability in key markets can affect operations and sales.
-
Currency Fluctuations:
- Exchange Rate Volatility: As Lupin operates in multiple countries, fluctuations in currency exchange rates can impact revenue and profit margins.
-
Intellectual Property Risks:
- Patent Expirations: As patents on key drugs expire, revenue from those products will decline unless new drugs can replace them.
- Patent Litigation: Ongoing legal battles over patent infringements can incur significant costs and distract from core business operations.
-
Technological Advancements:
- Failure to Adapt: The need for digital transformation and investment in technology to streamline operations and enhance product development is crucial. Falling behind competitors in this regard could be a disadvantage.
-
Public Health Crises:
- Emerging Infectious Diseases: The ongoing threat of pandemics and other public health crises can disrupt production and demand in specific therapeutic segments.
Navigating these risks will require strategic foresight, strong operational management, and an adaptable approach to changing market conditions. Investing in R&D, maintaining compliance, and leveraging technology will be crucial for Lupin Ltd to mitigate these challenges and sustain growth.
Revenue & Expenses Breakdown
Lupin Ltd
Balance Sheet Decomposition
Lupin Ltd
Current Assets | 134.5B |
Cash & Short-Term Investments | 25.3B |
Receivables | 59.3B |
Other Current Assets | 49.9B |
Non-Current Assets | 105.5B |
Long-Term Investments | 2.3B |
PP&E | 54.9B |
Intangibles | 41.6B |
Other Non-Current Assets | 6.7B |
Current Liabilities | 85B |
Accounts Payable | 29.6B |
Accrued Liabilities | 4.2B |
Short-Term Debt | 26.7B |
Other Current Liabilities | 24.5B |
Non-Current Liabilities | 12.1B |
Long-Term Debt | 1.6B |
Other Non-Current Liabilities | 10.5B |
Earnings Waterfall
Lupin Ltd
Revenue
|
208B
INR
|
Cost of Revenue
|
-67.4B
INR
|
Gross Profit
|
140.5B
INR
|
Operating Expenses
|
-110.3B
INR
|
Operating Income
|
30.2B
INR
|
Other Expenses
|
-7.6B
INR
|
Net Income
|
22.6B
INR
|
Free Cash Flow Analysis
Lupin Ltd
INR | |
Free Cash Flow | INR |
Lupin delivered impressive Q2 FY '25 results, with sales rising 11.3% year-on-year to INR 5,497 crores and a 13.7% increase for H1. In India, revenues surged by 19%, significantly outperforming market growth. The U.S. business saw a 3% revenue increase, supported by the launch of new products like Mirabegron. The company projects close to double-digit revenue growth in the U.S. for the fiscal year, targeting EBITDA margins between 22% and 23%. Additionally, a robust product pipeline in complex generics is set to enhance profitability moving forward.
What is Earnings Call?
LUPIN Profitability Score
Profitability Due Diligence
Lupin Ltd's profitability score is 55/100. The higher the profitability score, the more profitable the company is.
Score
Lupin Ltd's profitability score is 55/100. The higher the profitability score, the more profitable the company is.
LUPIN Solvency Score
Solvency Due Diligence
Lupin Ltd's solvency score is 71/100. The higher the solvency score, the more solvent the company is.
Score
Lupin Ltd's solvency score is 71/100. The higher the solvency score, the more solvent the company is.
Wall St
Price Targets
LUPIN Price Targets Summary
Lupin Ltd
According to Wall Street analysts, the average 1-year price target for LUPIN is 2 208.36 INR with a low forecast of 973.64 INR and a high forecast of 2 887.5 INR.
Dividends
Current shareholder yield for LUPIN is .
Shareholder yield represents the total return a company provides to its shareholders, calculated as the sum of dividend yield, buyback yield, and debt paydown yield. What is shareholder yield?
Ownership
LUPIN Insider Trading
Buy and sell transactions by insiders
Period | Sold | Bought | Net |
---|---|---|---|
3 Months |
|
|
|
6 Months |
|
|
|
9 Months |
|
|
|
12 Months |
|
|
|
Profile
Country
Industry
Market Cap
Dividend Yield
Description
Lupin Ltd. is an innovation led transnational pharmaceutical company, which engages in the manufacture of pharmaceutical products. The company is headquartered in Mumbai, Maharashtra and currently employs 19,789 full-time employees. The firm develops and commercializes a range of branded and generic formulations, biotechnology products, and active pharmaceutical ingredients (APIs) in over 100 markets in the United States, India, South Africa, and across the Asia Pacific, Latin America, and others. The company offers vitamins, minerals, supplements and neurological products. The company has presence in the cardiovascular, diabetology, asthma, pediatrics, central nervous system, gastro-intestinal, anti-infectives and nonsteroidal anti-inflammatory drug therapy segments. Its complex generics portfolio includes Filgrastim, Peg-Filgrastim, Etanercept and Albuterol, and others. Its biosimilar products include Filgrastim, Peg-Filgrastim and Etanercept. Its specialty products consist of Solosec and NaMuscla. Its over-the-counter products include Softovac, Lupizyme, Aptivate, Lupisafe, Be One and V-Bath, and others. The company supplies APIs for anti-retroviral, anti-malarial and others.
Contact
IPO
Employees
Officers
The intrinsic value of one LUPIN stock under the Base Case scenario is 1 418.64 INR.
Compared to the current market price of 2 071.35 INR, Lupin Ltd is Overvalued by 32%.